{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:29:34Z","timestamp":1763810974647,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Western guidelines recommend the use of intravenous iron supplementation for hemodialysis patients. However, in Japanese patients with well-controlled inflammation, iron replacement may be achieved with oral iron supplementation. This study involved 108 courses in 77 outpatient hemodialysis patients who received low-dose oral iron replacement therapy. Data from baseline to week 28 of treatment were analyzed to identify factors associated with effectiveness. Changes over time in erythrocyte- and iron-related parameters and erythropoiesis-stimulating agent (ESA) dose were investigated in the effective group. A total of 84 courses (77.8%) satisfied the effectiveness criteria. Compared with the effective and ineffective groups, only C-reactive protein (CRP) was significantly different (p &lt; 0.01). ROC curve analysis with efficacy as the endpoint showed a CRP cut point value of \u22640.1 mg\/dL (area under the curve, 0.69; 95% confidence interval, 0.57\u20130.81). The relationship between serum ferritin and hemoglobin fluctuation by reducing the ESA dose showed a positive correlation (p &lt; 0.001). In the ESA maintenance group, the serum ferritin gradually increased and then remained constant at about 60 ng\/mL. Our data suggest that patients with CRP \u2264 0.1 mg\/dL may benefit from low doses of oral iron supplementation. Approximately 60 ng\/mL serum ferritin may be sufficient during stable hematopoiesis.<\/jats:p>","DOI":"10.3390\/nu15010125","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T05:28:24Z","timestamp":1672205304000},"page":"125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-Dose Oral Iron Replacement Therapy Is Effective for Many Japanese Hemodialysis Patients: A Retrospective Observational Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Chie","family":"Ogawa","sequence":"first","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, Inc., Kawasaki 211-0063, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Biomarker Society, Inc., Kawasaki 211-0063, Japan"},{"name":"Department of Blood Purification, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineko","family":"Kanemitsu","sequence":"additional","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunimi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Maeda Institute of Renal Research, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, Inc., Kawasaki 211-0063, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Eisenga, M.F., Nolte, I.M., van der Meer, P., Bakker, S.J.L., and Gaillard, C.A.J.M. (2018). Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1021-3"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kuragano, T., Joki, N., Hase, H., Kitamura, K., Murata, T., Fujimoto, S., Fukatsu, A., Inoue, T., Itakura, Y., and Nakanishi, T. (2020). Low transferrin saturation (TSAT) and high ferritin levels are significant predictors for cerebrovascular and cardiovascular disease and death in maintenance hemodialysis patients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236277"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2018-05-815944","article-title":"Iron deficiency","volume":"133","author":"Camaschella","year":"2019","journal-title":"Blood"},{"key":"ref_4","first-page":"279","article-title":"Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"McMurray","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_6","first-page":"1381","article-title":"Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages","volume":"108","author":"Ganz","year":"2006","journal-title":"Best Pract. Res. Clin. Heamatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/16078454.2020.1720103","article-title":"The target hemoglobin content values of reticulocytes for efficient anemia improvement are achieved by low ferritin levels and moderate transferrin saturation: A retrospective observational study","volume":"25","author":"Ogawa","year":"2020","journal-title":"Hematology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous Iron in Patients Undergoing Maintenance Hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1536\/ihj.46.255","article-title":"Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease","volume":"46","author":"Reis","year":"2005","journal-title":"Int. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000035250.66458.67","article-title":"Iron Therapy, Advanced Oxidation Protein Products and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease","volume":"106","author":"Massy","year":"2002","journal-title":"Circulation"},{"key":"ref_12","first-page":"e2133935","article-title":"Risk of Infection Associated with Administration of Intravenous Iron: A Systematic Review and Meta-analysis","volume":"4","author":"Shah","year":"2021","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2012121164","article-title":"Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients","volume":"24","author":"Brookhart","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2215\/CJN.00420107","article-title":"Role of oral iron in the management of long-term hemodialysis patients","volume":"2","author":"Lenga","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100865","DOI":"10.1016\/j.mam.2020.100865","article-title":"Oral iron supplementation in iron-deficient women: How much and how often?","volume":"75","author":"Stoffel","year":"2020","journal-title":"Mol. Aspects Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1309\/AJCPQAX0JFHFS0OA","article-title":"Diagnosis of iron deficiency in patients undergoing hemodialysis","volume":"133","author":"Buttarello","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s101570300007","article-title":"Assessment of iron deficiency in chronic hemodialysis patients: Investigation of cutoff values for reticulocyte hemoglobin content","volume":"7","author":"Mitsuiki","year":"2003","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2009-10-251496","article-title":"Iron control of erythroid development by a novel aconitase-associated regulatory pathway","volume":"116","author":"Bullock","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-87-6-710","article-title":"Iron balance in hemodialysis patients","volume":"87","author":"Eschbach","year":"1977","journal-title":"Ann. Intern Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kuragano, T., Kitamura, K., Matsumura, O., Matsuda, A., Hara, T., Kiyomoto, H., Murata, T., Fujimoto, S., Hase, H., and Joki, N. (2016). ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147328"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/nep.13560","article-title":"Haemoglobin variability and all-cause mortality in haemodialysis patients: A systematic review and meta-analysis","volume":"24","author":"Zhao","year":"2019","journal-title":"Nephrology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000441573","article-title":"Differences in the Characteristics of Dialysis Patients in Japan Compared with Those in Other Countries Differences in the Characteristics of Dialysis Patients in Japan Compared with Those in Other Countries","volume":"40","author":"Kimata","year":"2015","journal-title":"Blood Purif."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1007\/s12011-021-02598-1","article-title":"The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: A Systematic Review and Time-Response Meta-Analysis","volume":"199","author":"Magzoub","year":"2021","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Iwasaki, T., Fujimori, A., Nakanishi, T., Okada, S., Hanawa, N., Hasuike, Y., and Kuragano, T. (2021). Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02320-2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.xkme.2020.01.007","article-title":"Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"2","author":"Karaboyas","year":"2020","journal-title":"Kidney Med."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/1\/125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:48Z","timestamp":1760147568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/1\/125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["nu15010125"],"URL":"https:\/\/doi.org\/10.3390\/nu15010125","relation":{},"ISSN":["2072-6643"],"issn-type":[{"type":"electronic","value":"2072-6643"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}